Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Multi-Center , Dose-Finding Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)
Conditions
Interventions
EPO-018B
Locations
1
China
Changzheng Hospital
Shanghai, Shanghai Municipality, China
Start Date
July 1, 2014
Primary Completion Date
December 1, 2015
Completion Date
December 1, 2015
Last Updated
February 19, 2015
NCT05012111
NCT03520647
NCT05447442
NCT06287268
NCT04645199
NCT03050268
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions